Novel targets for VEGF-independent anti-angiogenic drugs. - sprookjes - yvandenbroek - TriplyDB

Novel targets for VEGF-independent anti-angiogenic drugs.

Novel targets for VEGF-independent anti-angiogenic drugs.

http://www.wikidata.org/entity/Q37984612

about

Pazopanib and HDAC inhibitors interact to kill sarcoma cells.Angiogenesis-related pathways in the pathogenesis of ovarian cancer Angiogenic neovessels promote tissue hypoxia The Notch ligand Delta-like 4 (DLL4) as a target in angiogenesis-based cancer therapy?Activin receptor-like kinase 1 as a target for anti-angiogenesis therapy.PET radiopharmaceuticals for imaging integrin expression: tracers in clinical studies and recent developments.New therapeutic targets for cancer bone metastasis H-CRRETAWAC-OH, a lead structure for the development of radiotracer targeting integrin α5β1?Quantitative phosphoproteomics analysis reveals broad regulatory role of heparan sulfate on endothelial signaling.Abnormalities in alternative splicing of angiogenesis-related genes and their role in HIV-related cancers.Expressions and Clinical Significances of Angiopoietin-1, Angiopoietin-2, and Tie-2 Receptor in Patients With Colorectal Cancer Monitoring vascular normalization induced by antiangiogenic treatment with (18)F-fluoromisonidazole-PET.Tumor-secreted anterior gradient-2 binds to VEGF and FGF2 and enhances their activities by promoting their homodimerization.[Progress of platelet derived grow factor family in non-small cell lung cancer].

P2860

Q33631472-43DA75E4-2898-4968-99F6-8ECAA71D1913 Q37139109-E3C03169-BED1-4122-A44D-D3BC4231437E Q37281639-D9247EA1-7252-4A58-ACC4-0A9B929A608A Q37601970-5A2E93E1-9607-4FDB-95B2-EABA99D04C28 Q38140116-AD120F3A-5AF1-4AA1-8177-E3CE667D4E68 Q38228356-15D7CE23-659D-4DF6-9490-CC1A771DD6AD Q38473066-2176DAE9-E51E-4B26-9CE4-A2611045C798 Q38942329-31AF6D92-09C3-4BB5-A7A1-3C6DC1AEB9D3 Q39155470-F8751C0F-CF6B-4CC6-B6E9-756739B4BEEB Q39426973-D541BDFE-18BF-4A20-9776-70DEC177022C Q42086631-FBA5CE41-2A38-43C1-968F-FBCF46FA6629 Q42282877-1BAAE797-8B28-4D44-9502-5E853F5DD0C8 Q47898529-70902807-30D6-425F-868C-76B988133DD1 Q55464615-51D48F76-7E6A-4321-8748-32818ED57591

P2860

Novel targets for VEGF-independent anti-angiogenic drugs.

http://www.wikidata.org/entity/Q37984612

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Novel targets for VEGF-independent anti-angiogenic drugs.

@en

Novel targets for VEGF-independent anti-angiogenic drugs.

@nl

type

label

Novel targets for VEGF-independent anti-angiogenic drugs.

@en

Novel targets for VEGF-independent anti-angiogenic drugs.

@nl

prefLabel

Novel targets for VEGF-independent anti-angiogenic drugs.

@en

Novel targets for VEGF-independent anti-angiogenic drugs.

@nl

P1433

Q37984612-2FF70448-76AB-42F4-9A58-0638CAB0CC6E

P1476

Q37984612-6DDC7CA0-9478-456E-86AD-05151B8A0594

P2093

Q37984612-B1F33160-2851-4275-9AA4-BB4F25039EEF

Q37984612-E20EFBC5-C7C1-412E-B8FB-7CDC3C483D9C

P2860

Q37984612-063F83B1-18CA-40C8-83A4-9B4A18EE020F

Q37984612-0685824B-2D31-4C4C-8CE5-748A8DE68EC5

Q37984612-075CF4CA-B283-44F1-B48C-BB233CAE53C0

Q37984612-0B7B212A-D0FA-4CAE-A141-30911237368E

Q37984612-0CCE0B6E-3FCF-45DD-8CDE-2E3433DAFC10

Q37984612-0D2B024C-5BE6-478E-A688-A1406510EE58

Q37984612-0E081A15-22FB-4367-A7D5-1904B8512AF9

Q37984612-1133E0D5-D184-4189-B4A7-42280F5BDF6C

Q37984612-116B9135-6B69-487F-9AB1-6FCE2E47FBBA

Q37984612-1200F396-1C4C-4C89-9EE1-9220BF0E257A

P304

Q37984612-D37B1A49-0721-4B21-B36F-0FF3D8726790

P31

Q37984612-69F87260-C43C-4DE7-9AF5-C69DEEF463B2

P356

Q37984612-B395689D-353E-46BE-9FB8-E1EECC69E0B3

P407

Q37984612-A0822130-089C-43C9-9411-0C49C80AA625

P433

Q37984612-D7E16222-8828-4369-9CD6-6290CF3132A3

P478

Q37984612-44690E1C-2EB8-4B1C-8949-C76F78F71CD1

P50

Q37984612-57940F9C-E74C-432F-8EE0-3D771DD77099

P577

Q37984612-D4E460E2-F8BA-4692-B98B-3956BB80EF0B

P698

Q37984612-E3D86C6A-BCC9-48A3-B123-B88305CB42AB

P356

13543784.2012.661715

P1433

Expert Opinion on Investigational Drugs

P1476

Novel targets for VEGF-independent anti-angiogenic drugs

@en

P2093

Giovanni Scambia

http://www.w3.org/2001/XMLSchema#string

Marco Petrillo

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4

Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation

Activin receptor-like kinase 1 is implicated in the maturation phase of angiogenesis

Differential function of Tie2 at cell-cell contacts and cell-substratum contacts regulated by angiopoietin-1

Molecular cloning and characterization of the human and porcine transforming growth factor-beta type III receptors

Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

P304

451-472

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.2012.661715

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-02-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22339615

http://www.w3.org/2001/XMLSchema#string